The Effect of Short Treatment with Nigella Sativa on Symptoms, the Cluster of Differentiation (CD) Profile, and Inflammatory Markers in Mild COVID-19 Patients: A Randomized, Double-Blind Controlled Trial

Khalid A. Bin Abdulrahman, Abdullah Omar Bamosa, Abdullah I. Bukhari, Intisar Ahmad Siddiqui, Mostafa A. Arafa, Ashfaq A. Mohsin, Mamdouh Faleh Althageel, Majed Owed Aljuaeed, Ibrahim Mohammed Aldeailej, Abdulaziz Ibrahim Alrajeh, Kamel Mohamed Aldosari, Najat Ahmed Hawsawi, Khalid Ibrahim Zawbaee and Saad Mohammed Alsurayea
Additional contact information
Khalid A. Bin Abdulrahman: Department of Medical Education, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia
Abdullah Omar Bamosa: Department of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia
Abdullah I. Bukhari: Department of Medicine, Division of Infectious Diseases, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia
Intisar Ahmad Siddiqui: Department of Dental Education, College of Dentistry, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia
Mostafa A. Arafa: Cancer Research Chair, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia
Ashfaq A. Mohsin: Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia
Mamdouh Faleh Althageel: Ministry of Health, King Salman Bin Abdulaziz Hospital, Riyadh 12769, Saudi Arabia
Majed Owed Aljuaeed: Ministry of Health, King Salman Bin Abdulaziz Hospital, Riyadh 12769, Saudi Arabia
Ibrahim Mohammed Aldeailej: Ministry of Health, Riyadh Regional Lab and Blood Bank, Riyadh 12746, Saudi Arabia
Abdulaziz Ibrahim Alrajeh: Ministry of Health, Riyadh Regional Lab and Blood Bank, Riyadh 12746, Saudi Arabia
Kamel Mohamed Aldosari: Ministry of Health, Riyadh Regional Lab and Blood Bank, Riyadh 12746, Saudi Arabia
Najat Ahmed Hawsawi: Ministry of Health, Riyadh Regional Lab and Blood Bank, Riyadh 12746, Saudi Arabia
Khalid Ibrahim Zawbaee: Ministry of Health, Riyadh Regional Lab and Blood Bank, Riyadh 12746, Saudi Arabia
Saad Mohammed Alsurayea: Ministry of Health, Riyadh Regional Lab and Blood Bank, Riyadh 12746, Saudi Arabia

IJERPH, 2022, vol. 19, issue 18, 1-14

Abstract: The current study investigated the impact of different doses of Nigella sativa seeds on the symptoms, the cluster of differentiation profile group, and inflammatory markers of mild COVID-19 cases. Methods: The study was a double-blind placebo-controlled clinical trial. Patients with mild and asymptomatic SARS-CoV-2 infection patients were randomly subdivided into seven subgroups: Group (GP) 1: received charcoal capsules as a control group, and GP 2: received three capsules of whole Nigella sativa seeds daily, two capsules in the morning and one in the evening; GP 3: received three capsules of whole Nigella sativa seeds every 12 h, GP 4: received five capsules in the morning and four capsules of whole Nigella sativa seeds in the evening, GP 5: received one capsule of Nigella sativa powder every 12 h; GP 6: received two capsules of Nigella sativa powder every 12 h; GP 7: received three capsules of Nigella sativa powder every 12 h; all treatment course was for ten days. Inflammatory parameters were assessed before and after interventions. Results: 262 subjects were included in the final analysis. No significant difference was detected regarding age, gender, and nationality. No significant differences were detected between the inflammatory marker in all groups. The WBCs showed a significant difference between before and after the intervention. While for procalcitonin, a significant difference was demonstrated in groups 1,4, and 6. Conclusions: The current randomized clinical trial did not reveal a significant effect of ten days of treatment with various doses of Nigella sativa on symptoms, differentiation profile, and inflammatory markers of patients with COVID-19. As a natural product, the effect of Nigella sativa on disease requires weeks to manifest itself.

Keywords: mild COVID-19; Nigella sativa; anti-inflammatory; randomized clinical trial; Saudi Arabia (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/18/11798/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/18/11798/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:18:p:11798-:d:918582

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().